Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) rose 11.2% during mid-day trading on Tuesday . The company traded as high as $8.27 and last traded at $8.14, with a volume of 57,657 shares traded. The stock had previously closed at $7.32.

XENE has been the subject of a number of recent research reports. Zacks Investment Research downgraded Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 7th. Jefferies Group reissued a “buy” rating and issued a $13.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, May 11th.

The company’s market capitalization is $117.10 million. The firm’s 50-day moving average is $6.73 and its 200 day moving average is $7.05.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by $0.02. On average, equities analysts anticipate that Xenon Pharmaceuticals Inc. will post ($1.62) EPS for the current year.

In other Xenon Pharmaceuticals news, CFO Ian Mortimer purchased 5,300 shares of the stock in a transaction that occurred on Friday, June 24th. The stock was purchased at an average price of $6.22 per share, with a total value of $32,966.00. Following the acquisition, the chief financial officer now owns 1,000 shares in the company, valued at $6,220. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Xenon Pharmaceuticals Inc (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.